Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial

Journal of Infectious Diseases

Volumn 203, Issue 7, 2011, Pages 976-983

  Li, Jonathan Z ^a,b   Brumme, Zabrina L ^c,d   Brumme, Chanson J ^c   Wang, Hongying ^e   Spritzler, John ^e   Robertson, Michael N ^f   Lederman, Michael M ^g   Carrington, Mary ^c,h   Walker, Bruce D ^b,c,i   Schooley, Robert T ^j   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d SIMON FRASER UNIVERSITY   (Canada)

^e CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h SAIC FREDERICK INC   (United States)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; POL PROTEIN; VIRUS RNA;

ALLELE; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; REBOUND; RNA SEQUENCE; UNINDEXED SEQUENCE; VIRUS CELL INTERACTION; VIRUS LOAD;

ADENOVIRIDAE; AIDS VACCINES; DRUG CARRIERS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; PLACEBOS; PLASMA; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; TREATMENT OUTCOME; VACCINATION; VIRAL LOAD;

EID: 79953018441     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq143     Document Type: Article

References (43)

1. + lymphocytes. Science 1999; 283:857-60.
2. + T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-8.
3. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5. (Pubitemid 24183063)
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
5. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74. (Pubitemid 27461281)
6. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-9.
7. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010; 202:705-16.
8. Schooley RWH, Spritzler J, Lederman M, et al. the AIDS Clinical Trials Group. Therapeutic vaccination with a replication defective adenovirus type 5 HIV-1 gag vaccine in a prospective double-blinded, placebocontrolled trial (ACTG 5197). In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA3-6 February 2008.
9. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619-30.
10. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLAB in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-75.
11. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-43. (Pubitemid 34553083)
12. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-51. (Pubitemid 37386411)
13. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-5.
14. Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 2009; 4:e6687.
15. Honeyborne I, Prendergast A, Pereyra F, et al. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 2007; 81:3667-72. (Pubitemid 46456679)
16. Leslie A, Kavanagh D, Honeyborne I, et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 2005; 201: 891-902. (Pubitemid 40524459)
17. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581-91. (Pubitemid 38402336)
18. + T cell response against HIV-1. PLoS Med 2006; 3:e403.
19. Frater AJ, Brown H, Oxenius A, et al. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol 2007; 81:6742-51. (Pubitemid 46878078)
20. Matthews PC, Prendergast A, Leslie A, et al. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol 2008; 82:8548-59.
21. Gao X, Nelson GW, Karacki P, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344:1668-75. (Pubitemid 32479964)
22. +-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol 2002; 76:12603-10.
23. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-9. (Pubitemid 34062178)
24. Ioannidis JP, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. AIDS 2000; 14:1481-8.
25. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163:1220-6. (Pubitemid 36613076)
26. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
27. Altfeld M, Addo MM, Shankarappa R, et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003; 77:7330-40. (Pubitemid 36734501)
28. Tobery TW, Dubey SA, Anderson K, et al. A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses 2006; 22:1081-90. (Pubitemid 44904257)
29. Trigona WL, Clair JH, Persaud N, et al. Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses. J Interferon Cytokine Res 2003; 23:369-77. (Pubitemid 36876283)
30. Bhattacharya T, Daniels M, Heckerman D, et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007; 315:1583-6. (Pubitemid 46449476)
31. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53. (Pubitemid 46067385)
32. Crawford H, Lumm W, Leslie A, et al. Evolution of HLA-B* 5703HIV-1 escapemutations inHLA-B*5703-positive individuals and their transmission recipients. J Exp Med 2009; 206:909-21.
33. Frahm N, McElrath MJ. Recent immunologic findings from the Step and related HIV vaccine clinical trials. In: AIDS Vaccine Conference. Paris, France, 19-22 October 2009.
34. Liu Y, McNevin J, Zhao H, et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 2007; 81:12179-88. (Pubitemid 350085833)
35. Goepfert PA, Lumm W, Farmer P, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008; 205:1009-17. (Pubitemid 351679677)
36. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003; 61:403-7.
37. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007; 68:779-88. (Pubitemid 47379974)
38. Gloster SE, Newton P, Cornforth D, et al. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004; 18:749-55. (Pubitemid 38535002)
39. + T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol 2004; 78:12638-46.
40. + T cells. J Exp Med 2004; 200:701-12.
41. Carlson JM, Brumme ZL. HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes Infect 2008; 10:455-61.
42. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-23.
43. Brumme ZL, Tao I, Szeto S, et al. Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS 2008; 22:1277-86.